These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33389549)

  • 1. PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT.
    Henrich A; Juif PE; Dingemanse J; Krause A
    J Pharmacokinet Pharmacodyn; 2021 Apr; 48(2):213-224. PubMed ID: 33389549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist Clazosentan.
    Juif PE; Dingemanse J; Voors-Pette C; Ufer M
    AAPS J; 2020 Aug; 22(5):103. PubMed ID: 32748293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist.
    van Giersbergen PL; Dingemanse J
    Eur J Clin Pharmacol; 2007 Feb; 63(2):151-8. PubMed ID: 16636870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of gender on the tolerability, safety and pharmacokinetics of clazosentan following long-term infusion.
    van Giersbergen PL; Dingemanse J
    Clin Drug Investig; 2007; 27(11):797-802. PubMed ID: 17914898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of severe renal impairment on the pharmacokinetics of clazosentan.
    Bruderer S; Sasu B; Tsvitbaum N; Dingemanse J
    J Clin Pharmacol; 2011 Mar; 51(3):413-21. PubMed ID: 20926750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan.
    Bruderer S; Detishin V; Tsvitbaum N; Dingemanse J
    Br J Clin Pharmacol; 2011 Jan; 71(1):52-60. PubMed ID: 21143501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean Patients.
    Fujimura M; Joo JY; Kim JS; Hatta M; Yokoyama Y; Tominaga T
    Cerebrovasc Dis; 2017; 44(1-2):59-67. PubMed ID: 28463833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists.
    Volz AK; Dingemanse J; Krause A; Lehr T
    Pharm Res; 2019 Dec; 37(1):2. PubMed ID: 31823033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Rifampin-Mediated Organic Anion-Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan.
    Juif PE; Voors-Pette C; Ufer M; Dogterom P; Dingemanse J
    Clin Transl Sci; 2019 Sep; 12(5):440-444. PubMed ID: 31004470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage.
    Zisowsky J; Fuseau E; Bruderer S; Krause A; Dingemanse J
    Eur J Clin Pharmacol; 2014 Apr; 70(4):409-19. PubMed ID: 24458541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series.
    Barth M; Capelle HH; Münch E; Thomé C; Fiedler F; Schmiedek P; Vajkoczy P
    Acta Neurochir (Wien); 2007; 149(9):911-8; discussion 918. PubMed ID: 17700991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects.
    Oberoi RK; Zhao W; Rosebraugh M; Mensa F; Wang H; Liu W
    Clin Ther; 2020 Jul; 42(7):1317-1329. PubMed ID: 32622784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, Four-Period Crossover Study To Evaluate the Effect of Gepotidacin on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram in Healthy Volunteers.
    Hossain M; Zhou M; Tiffany C; Dumont E; Darpo B
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No QTc Prolongation With Zanubrutinib: Results of Concentration-QTc Analysis From a Thorough QT Study in Healthy Subjects.
    Mu S; Darpo B; Tang Z; Novotny W; Tawashi M; Xue H; Willett M; Lin L; Sahasranaman S; Ou YC
    Clin Transl Sci; 2020 Sep; 13(5):923-931. PubMed ID: 32144955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous Amisulpride Does Not Meaningfully Prolong the QTc Interval at Doses Effective for the Management of Postoperative Nausea and Vomiting.
    Fox GM; Albayaty M; Walker JL; Xue H; Darpo B
    Anesth Analg; 2021 Jan; 132(1):150-159. PubMed ID: 31913911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
    Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
    Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial.
    Macdonald RL; Kassell NF; Mayer S; Ruefenacht D; Schmiedek P; Weidauer S; Frey A; Roux S; Pasqualin A;
    Stroke; 2008 Nov; 39(11):3015-21. PubMed ID: 18688013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
    Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
    Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of ethnic origin and sex on the pharmacokinetics of clazosentan.
    van Giersbergen PL; Gunawardena KA; Dingemanse J
    J Clin Pharmacol; 2007 Nov; 47(11):1374-80. PubMed ID: 17906281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced QT prolongation when QT interval is measured in each of the 12 ECG leads in men and women in a thorough QT study.
    Panicker GK; Salvi V; Karnad DR; Chakraborty S; Manohar D; Lokhandwala Y; Kothari S
    J Electrocardiol; 2014; 47(2):155-7. PubMed ID: 24388488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.